FDA's rare disease framework could center patient identification

An FDA notice seeking public input is under review at the Office of Management and Budget, according to a Citeline report on October 12, 2026. The notice suggests FDA wants to consolidate its scattered rare disease flexibilities into one structured framework. As of October 13, it had not been published in the Federal Register , so its content, scope and timing are unknown.